The entire field of migraine is witnessing a profound and unprecedented transformation with new therapeutic options now available to address serious unmet medical needs and patient burden. The new options range from monoclonal antibodies (mAbs) targeting the CGRP ligand or receptor for migraine prevention, to a selective serotonin agonist, to oral CGRP-targeting agents (gepants) now approved for both preventive and acute treatment. These new advances are creating a vitality and excitement in the field not seen since the advent of triptans more than 2 decades ago.

Learning Objectives

  • Identify gaps in the quality of care provided to patients with migraine, the disability and socioeconomic impact on patient quality of life, and opportunities to improve outcomes.
  • Summarize the efficacy and adverse effects of older or non-specifically-targeted migraine therapies.
  • Choose new migraine-specific therapies for acute and preventive treatment in appropriate patients by using efficacy and tolerability data from clinical trials.


Stewart J. Tepper, MD, FAHS

Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Merle Diamond, MD

Clinical Assistant Professor
Department of Medicine
Rosalind Franklin Universty of Medicine and Science/Chicago Medical School
President and Managing Director
Diamond Headache Clinic
Chicago, IL


The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Stewart J. Tepper, MD: Advisory Board for Aeon, Allergan/AbbVie, Amgen, Axsome Therapeutics, CoolTech, Eli Lilly, Impel, Lundbeck, Neurolief, Novartis, Satsuma, Theranica, XOC, Zosano. Consultant for Aeon, Allergan/AbbVie, Alphasights, Amgen, Atheneum, Axsome Therapeutics, Becker Pharmaceutical Consulting, ClearView. Contracted Research for Allergan/AbbVie, Amgen, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, Zosano.

Merle L. Diamond, MD: Speaker’s Bureau for Amgen, Allergan, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Lundbeck, Impel. Advisory Board for Lundbeck Pharmaceuticals, Amgen, Assertio Therapeutics, Axsome Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Upsher-Smith Laboratories. Consultant for Lundbeck Pharmaceuticals, Amgen, Eli Lilly & Co., Teva Pharmaceuticals, Promius Pharma. Contracted Research for Allergan, Amgen, Lilly, Teva, Lundbeck.

Ty J. Gluckman, MD, FACC, FAHA (moderator): No relevant financial relationships disclosed.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians. 

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.  


Designation Statement

This activity is approved for 1.00 contact hour of continuing education, which includes 0.66 hours of pharmacology.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Commercial Supporter

Biohaven Pharmaceuticals

Education Partner

Miller Medical Communications, LLC

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

View more pharmacology CME/CE courses.